Essential to care Q1 FY 2008 Earnings Call FY 2008 November 5, 2007 Exhibit 99.3 |
2 Forward-looking statements and GAAP reconciliation This presentation contains forward-looking statements addressing expectations, prospects, estimates and other matters that are dependent upon future events or developments. These matters are subject to risks and uncertainties that could cause actual results to differ materially from those projected, anticipated or implied. The most significant of these uncertainties are described in Cardinal Health's Form 10-K, Form 10-Q and Form 8-K reports (including all amendments to those reports) and exhibits to those reports, and include (but are not limited to) the following: competitive pressures in its various lines of business; the loss of one or more key customer or supplier relationships or changes to the terms of those relationships; uncertainties relating to the timing of generic introductions and the frequency or rate of branded pharmaceutical price appreciation or generic pharmaceutical price deflation; changes in the distribution patterns or reimbursement rates for healthcare products and/or services; the results, consequences, effects or timing of any inquiry or investigation by any regulatory authority or any legal and administrative proceedings; successful integration of Cardinal Health and VIASYS Healthcare and the ability to achieve synergies from the acquisition; uncertainties relating to the amount of future share repurchases by Cardinal Health, which can be affected by Cardinal Health's then current stock price, regulatory restraints on share repurchases, cash flows, financial condition and alternative uses of cash available to Cardinal Health at the time, as well as by the amount of any additional share repurchases authorized by the board of directors; and general economic and market conditions. This presentation reflects management’s views as of November 5, 2007. Except to the extent required by applicable law, Cardinal Health undertakes no obligation to update or revise any forward-looking statement. In addition, this presentation includes non-GAAP financial measures. Cardinal Health provides definitions and reconciling information at the end of this presentation and on its investor relations page at www.cardinalhealth.com. |
3 Agenda Opening remarks Kerry Clark Chief Executive Officer Financial overview Jeff Henderson Chief Financial Officer Q&A |
4 Financial Overview • FY 2008 Q1 Results – Consolidated • FY 2008 Q1 Results – Business Segments • Key Financial Value Drivers • FY 2008 Financial Targets and Goals • HSCS Priorities |
5 Q1 FY 2008 Recap $21,973 $490 $303 $0.82 $409 16.7% ($M) 5% 9% 4% 15% % Change¹ GAAP Basis $512 $318 $0.86 17.5% ($M) 8% 3% 15% % Change¹ Non-GAAP Basis 1 % change over prior year quarter Revenue Operating Earnings Earnings from continuing ops Diluted EPS from continuing ops Operating cash flow Return on equity |
6 Operating Earnings/(Loss) ($M) Diluted EPS from Continuing Operations Operating Earnings/(Loss) ($M) Diluted EPS from Continuing Operations GAAP Consolidated $490 $0.82 $451 $0.71 Special Items ($23) ($0.04) ($22) ($0.04) Impairment Charges & Other $0 $0.00 ($2) $0.00 Non-GAAP Consolidated $512 $0.86 $475 $0.75 Q1 FY 2008 Q1 FY 2007 Q1 Operating Earnings and EPS |
7 Healthcare Supply Chain Services – Pharmaceutical Business Analysis Highlights: • Q1 revenue up 4% on new bulk revenue from existing customers and branded price inflation, partially offset by pharma market growth moderation, FY07 customer losses and soft nuclear market • Segment profit growth positively impacted by brand price inflation, improved operating leverage, and a $14M vendor related reserve reduction • Q1 segment profit negatively impacted by revenue growth/mix, fewer generic launches vs. last year and generic deflation • Corporate allocation change positively impacted segment profit growth by ~2 pps • Economic profit margin¹ increased 3 basis points vs. prior year to 0.88% Revenue Segment Profit 19,221 305 Q1 FY08 ($M) 18,553 289 Q1 FY07 ($M) 4% 6% % Change 1 Non-GAAP financial measure |
8 Healthcare Supply Chain Services – Medical Business Analysis Highlights: • Q1 revenue up 6% on new customer sales and improving demand from hospital, laboratory, and ambulatory customers, somewhat offset by demand in kitting products • Segment profit down 10%, driven by refined corporate allocation, operational investments (e.g., customer service), and higher costs within kitting • McGaw Park transition is on track with minimal business interruption • Corporate allocation change negatively impacted segment profits by ~9 pps Revenue Segment Profit 1,921 58 Q1 FY08 ($M) 1,806 64 Q1 FY07 ($M) 6% (10%) % Change |
9 Medical Products and Technologies Business Analysis Highlights: • Q1 revenue up 47% driven by the VIASYS acquisition, new product launches, increased penetration of existing customers, and foreign exchange • Segment profit up 24%, with margin dampened by purchase accounting impact from VIASYS acquisition • Overall VIASYS integration on-track; FY08 synergy capture ahead of schedule Revenue Segment Profit 623 57 Q1 FY08 ($M) 424 46 Q1 FY07 ($M) 47% 24% % Change |
10 Clinical Technologies and Services Business Analysis Highlights: • Q1 revenue up 9% on continued strong demand for infusion and dispensing products • Segment profit up 91%, driven by favorable product mix driving higher gross margins and improved operating leverage • Favorable compare vs. Q1 FY07 due to SE recall related charge of $13.5M in prior year • Segment profit margin up 640 bps vs. Q1 FY07 Revenue Segment Profit 649 98 Q1 FY08 ($M) 594 51 Q1 FY07 ($M) 9% 91% % Change |
11 Key Financial Value Drivers Balance sheet management – Days of inventory on hand declined from 30 to 28 days Q1 FY08 vs. Q1 FY07 – Portfolio optimization process ongoing – Non-GAAP ROIC up 157 bps vs. Q1 last year Capital deployment – $592M in share buyback completed in Q1, $720M since July 1st Capital structure – Debt to total capital increased from 26% in Q1 FY07 to 35% in Q1 FY08 – Net debt to capital¹ increased to 26% vs. 11% in Q1 last year – Non-GAAP effective tax rate for the quarter was 32.25% vs. 29.4% last year Non-GAAP Return on Equity increased 390 bps to 17.5% 1 Non-GAAP financial measure |
12 Outlook • Reconfirming overall Non-GAAP EPS guidance of $3.95 to $4.15 • 3 of 4 segments on-track — no change • Lowering guidance on Supply Chain Pharma to “Below range” • Profit growth significantly weighted toward latter part of 2 nd half – Difficult Q2 compare in Pharma |
November 5, 2007 Financial targets and goals In-line Strong investment grade Credit Rating: Completed $3.1B PTS-related share repurchase in July 2007; Announced new 2-year, $2B authorization - Quarterly dividend $0.12 per share - up to 50% of OCF, via share repurchase and dividends Cash Returned to Shareholders: In line with long-term goal > 100% of net earnings Operating Cash Flow: In line with long-term goal 15% - 20% Return on Equity 4 : In range + 20 - 25% + 10 - 15% CTS Above range + 25 - 30% + 8 - 12% MPT Below range³ + 6 - 9% + 4 - 7% HSCS - Medical Below range³ + 7 - 10% + 7 - 10% HSCS - Pharma FY08 profit growth vs. long-term goal Segment Profit Revenue Segment $3.95 - $4.15 per share + 12 - 16% EPS²: In range + 10 - 13% Op Earnings¹: In range + 8 - 10% Revenue: Fiscal Year 2008 Over FY'08 - FY'10 3 Year Period: One Year Targets Long-Term Financial Goals 1 Non-GAAP operating earnings 2 Non-GAAP diluted EPS from continuing operations 3 Refined methodology for allocation of corporate costs within HSCS in FY08 positively impacts HSCS-P profit growth by 1.8 percentage points, and negatively impacts HSCS-M profit growth by 7.3 percentage points 4 Non-GAAP return on equity |
14 HSCS Priorities HSCS – Medical: • Focus on acute care revenue growth and profitability • Leverage scale to lower product costs; expand off-shore sourcing • Continuing focusing on operational improvements in Presource ® kitting business • Complete McGaw Park transition HSCS – Pharmaceutical: • Drive initiatives in place to improve operational performance within core pharma distribution – Deliver on planned cost reductions – Revitalize retail selling organization and product capabilities – Execute strategy to enhance customer profitability through contract/generic compliance – Continue to drive generic sourcing and customer offering strategies • Within nuclear pharmacy services, adjust operating model to offset short-term market volatility – Longer-term, leverage Cardiolite generic event • Accelerate restructuring to improve operating leverage and to better align resources |
CARDINAL HEALTH, INC. AND SUBSIDIARIES
GAAP / NON-GAAP RECONCILIATION
(in millions)
HEALTHCARE SUPPLY CHAIN SERVICES
Pharmaceutical
| | | | | | | | | | | | | | | | | | | | | | | | | | |
| | First Quarter Fiscal 2008 | | | First Quarter Fiscal 2007 | |
| | July | | August | | September | | Total | | | July | | August | | September | | Total | |
Economic Profit Margin | | | | | | | | | | | | | | | | | | | | | | | | | | |
Segment profit | | | | | | | | | | | $ | 305.4 | | | | | | | | | | | | $ | 288.7 | |
Effective tax rate from continuing operations | | | | | | | | | | | | 35.9 | % | | | | | | | | | | | | 35.1 | % |
| | | | | | | | | | | | | | | | | | | | | | | | | | |
Net operating earnings, after-tax (NOPAT) | | | | | | | | | | | $ | 195.6 | | | | | | | | | | | | $ | 187.5 | |
| | | | | | | | |
Total assets | | $ | 11,591.6 | | $ | 11,719.5 | | $ | 11,574.7 | | | | | | $ | 11,549.8 | | $ | 12,206.9 | | $ | 11,620.0 | | | | |
Less: assets from discontinued operations | | | — | | | — | | | — | | | | | | | 107.5 | | | 109.4 | | | — | | | | |
Less: accounts payable | | | 7,350.3 | | | 7,948.1 | | | 8,344.0 | | | | | | | 7,488.3 | | | 8,027.1 | | | 8,101.0 | | | | |
Less: other accrued liabilities | | | 1,211.8 | | | 1,173.2 | | | 1,130.7 | | | | | | | 1,069.5 | | | 1,088.6 | | | 1,016.3 | | | | |
Less: liabilities from businesses held for sale | | | — | | | — | | | — | | | | | | | — | | | — | | | — | | | | |
Less: deferred income taxes and other liabilities | | | 88.8 | | | 86.7 | | | 35.0 | | | | | | | 82.1 | | | 82.1 | | | 71.0 | | | | |
Less: goodwill and other intangibles, net | | | 1,351.2 | | | 1,344.9 | | | 1,345.2 | | | | | | | 1,354.5 | | | 1,361.8 | | | 1,332.4 | | | | |
Less: cash and equivalents | | | 65.4 | | | 51.4 | | | 38.3 | | | | | | | 42.2 | | | 57.4 | | | 75.0 | | | | |
Less: short-term investments available for sale | | | — | | | — | | | — | | | | | | | — | | | — | | | — | | | | |
| | | | | | | | | | | | | | | | | | | | | | | | | | |
Tangible capital | | $ | 1,524.1 | | $ | 1,115.2 | | $ | 681.5 | | $ | 1,106.9 | | | $ | 1,405.7 | | $ | 1,480.5 | | $ | 1,024.3 | | $ | 1,303.5 | |
Multiplied by weighted average cost of capital | | | | | | | | | | | | 2.3 | % | | | | | | | | | | | | 2.3 | % |
| | | | | | | | | | | | | | | | | | | | | | | | | | |
Capital charge | | | | | | | | | | | $ | 25.5 | | | | | | | | | | | | $ | 30.0 | |
Economic profit | | | | | | | | | | | $ | 170.1 | | | | | | | | | | | | $ | 157.5 | |
Revenue | | | | | | | | | | | $ | 19,220.8 | | | | | | | | | | | | $ | 18,532.8 | |
Economic profit margin | | | | | | | | | | | | 0.88 | % | | | | | | | | | | | | 0.85 | % |
(1) | Tangible Capital is a quarterly average calculated as total assets allocated to the segment less (total liabilities allocated to the segment, goodwill and intangibles, cash and equivalents and short term investments available for sale) |
(2) | The sum of the components may not equal the total due to rounding |
(3) | Healthcare Supply Chain Services—Pharmaceutical Tangible Capital calculated for both current and prior fiscal year includes an allocation of payables previously held at Corporate to more accurately reflect the payable balance of the segment. |
CARDINAL HEALTH, INC. AND SUBSIDIARIES
GAAP / NON-GAAP RECONCILIATION
(in millions)
HEALTHCARE SUPPLY CHAIN SERVICES
Medical
| | | | | | | | | | | | | | | | | | | | | | | | | | |
| | First Quarter Fiscal 2008 | | | First Quarter Fiscal 2007 | |
| | July | | August | | September | | Total | | | July | | August | | September | | Total | |
Economic Profit Margin | | | | | | | | | | | | | | | | | | | | | | | | | | |
Segment profit | | | | | | | | | | | $ | 57.5 | | | | | | | | | | | | $ | 64.1 | |
Effective tax rate from continuing operations | | | | | | | | | | | | 29.3 | % | | | | | | | | | | | | 29.8 | % |
| | | | | | | | | | | | | | | | | | | | | | | | | | |
Net operating earnings, after-tax (NOPAT) | | | | | | | | | | | $ | 40.6 | | | | | | | | | | | | $ | 45.0 | |
| | | | | | | | |
Total assets | | $ | 2,481.8 | | $ | 2,515.4 | | $ | 2,552.6 | | | | | | $ | 2,442.1 | | $ | 2,437.6 | | $ | 2,456.6 | | | | |
Less: assets from discontinued operations | | | — | | | — | | | — | | | | | | | — | | | — | | | — | | | | |
Less: accounts payable | | | 539.0 | | | 581.0 | | | 615.0 | | | | | | | 534.8 | | | 478.7 | | | 510.4 | | | | |
Less: other accrued liabilities | | | 67.0 | | | 71.7 | | | 53.5 | | | | | | | 71.1 | | | 78.1 | | | 49.4 | | | | |
Less: liabilities from businesses held for sale | | | — | | | — | | | — | | | | | | | — | | | — | | | — | | | | |
Less: deferred income taxes and other liabilities | | | 54.6 | | | 55.4 | | | 61.3 | | | | | | | 58.2 | | | 58.1 | | | 53.0 | | | | |
Less: goodwill and other intangibles, net | | | 386.0 | | | 385.9 | | | 388.2 | | | | | | | 378.8 | | | 377.8 | | | 377.7 | | | | |
Less: cash and equivalents | | | 24.4 | | | 25.7 | | | 21.6 | | | | | | | 2.9 | | | 3.0 | | | 4.1 | | | | |
Less: short-term investments available for sale | | | — | | | — | | | — | | | | | | | — | | | — | | | — | | | | |
| | | | | | | | | | | | | | | | | | | | | | | | | | |
Tangible capital | | $ | 1,410.8 | | $ | 1,395.7 | | $ | 1,413.0 | | $ | 1,406.5 | | | $ | 1,396.3 | | $ | 1,441.9 | | $ | 1,462.0 | | $ | 1,433.4 | |
Multiplied by weighted average cost of capital | | | | | | | | | | | | 2.3 | % | | | | | | | | | | | | 2.3 | % |
| | | | | | | | | | | | | | | | | | | | | | | | | | |
Capital charge | | | | | | | | | | | $ | 32.3 | | | | | | | | | | | | $ | 33.0 | |
Economic profit | | | | | | | | | | | $ | 8.3 | | | | | | | | | | | | $ | 12.0 | |
Revenue | | | | | | | | | | | $ | 1,920.7 | | | | | | | | | | | | $ | 1,806.1 | |
Economic profit margin | | | | | | | | | | | | 0.43 | % | | | | | | | | | | | | 0.66 | % |
(1) | Tangible Capital is a quarterly average calculated as total assets allocated to the segment less (total liabilities allocated to the segment, goodwill and intangibles, cash and equivalents and short term investments available for sale) |
(2) | The sum of the components may not equal the total due to rounding |
CARDINAL HEALTH, INC. AND SUBSIDIARIES
GAAP / NON-GAAP RECONCILIATION
(in millions)
CLINICAL AND MEDICAL PRODUCTS
Clinical Technologies and Services
| | | | | | | | | | | | | | | | | | | | | | | | | | |
| | First Quarter Fiscal 2008 | | | First Quarter Fiscal 2007 | |
| | July | | August | | September | | Total | | | July | | August | | September | | Total | |
Economic Profit Margin | | | | | | | | | | | | | | | | | | | | | | | | | | |
Segment profit | | | | | | | | | | | $ | 98.3 | | | | | | | | | | | | $ | 51.5 | |
Effective tax rate from continuing operations | | | | | | | | | | | | 24.2 | % | | | | | | | | | | | | 29.2 | % |
| | | | | | | | | | | | | | | | | | | | | | | | | | |
Net operating earnings, after-tax (NOPAT) | | | | | | | | | | | $ | 74.5 | | | | | | | | | | | | $ | 36.5 | |
| | | | | | | | |
Total assets | | $ | 4,375.8 | | $ | 4,301.6 | | $ | 4,262.2 | | | | | | $ | 3,916.6 | | $ | 4,012.1 | | $ | 3,880.1 | | | | |
Less: assets from discontinued operations | | | — | | | — | | | — | | | | | | | — | | | — | | | — | | | | |
Less: accounts payable | | | 82.0 | | | 63.3 | | | 62.3 | | | | | | | 91.2 | | | 84.7 | | | 79.4 | | | | |
Less: other accrued liabilities | | | 575.9 | | | 592.2 | | | 250.3 | | | | | | | 277.2 | | | 287.9 | | | 223.4 | | | | |
Less: liabilities from businesses held for sale | | | — | | | — | | | — | | | | | | | — | | | — | | | — | | | | |
Less: deferred income taxes and other liabilities | | | 238.4 | | | 238.9 | | | 474.5 | | | | | | | 577.6 | | | 577.0 | | | 475.1 | | | | |
Less: goodwill and other intangibles, net | | | 2,171.8 | | | 2,206.2 | | | 2,180.4 | | | | | | | 2,085.9 | | | 2,083.4 | | | 2,174.3 | | | | |
Less: cash and equivalents | | | 217.3 | | | 195.5 | | | 175.4 | | | | | | | 66.2 | | | 60.1 | | | 82.6 | | | | |
Less: short-term investments available for sale | | | — | | | — | | | — | | | | | | | — | | | — | | | 0.3 | | | | |
| | | | | | | | | | | | | | | | | | | | | | | | | | |
Tangible capital | | $ | 1,090.4 | | $ | 1,005.5 | | $ | 1,119.3 | | $ | 1,071.7 | | | $ | 818.5 | | $ | 919.0 | | $ | 845.0 | | $ | 860.8 | |
Multiplied by weighted average cost of capital | | | | | | | | | | | | 2.3 | % | | | | | | | | | | | | 2.3 | % |
| | | | | | | | | | | | | | | | | | | | | | | | | | |
Capital charge | | | | | | | | | | | $ | 24.6 | | | | | | | | | | | | $ | 19.8 | |
Economic profit | | | | | | | | | | | $ | 49.9 | | | | | | | | | | | | $ | 16.7 | |
Revenue | | | | | | | | | | | $ | 648.9 | | | | | | | | | | | | $ | 594.5 | |
Economic profit margin | | | | | | | | | | | | 7.69 | % | | | | | | | | | | | | 2.81 | % |
(1) | Tangible Capital is a quarterly average calculated as total assets allocated to the segment less (total liabilities allocated to the segment, goodwill and intangibles, cash and equivalents and short term investments available for sale) |
(2) | The sum of the components may not equal the total due to rounding |
CARDINAL HEALTH, INC. AND SUBSIDIARIES
GAAP / NON-GAAP RECONCILIATION
(in millions)
CLINICAL AND MEDICAL PRODUCTS
Medical Products and Technologies
| | | | | | | | | | | | | | | | | | | | | | | | | | |
| | First Quarter Fiscal 2008 | | | First Quarter Fiscal 2007 | |
| | July | | August | | September | | Total | | | July | | August | | September | | Total | |
Economic Profit Margin | | | | | | | | | | | | | | | | | | | | | | | | | | |
Segment profit | | | | | | | | | | | $ | 56.9 | | | | | | | | | | | | $ | 46.0 | |
Effective tax rate from continuing operations | | | | | | | | | | | | 13.1 | % | | | | | | | | | | | | 7.0 | % |
| | | | | | | | | | | | | | | | | | | | | | | | | | |
Net operating earnings, after-tax (NOPAT) | | | | | | | | | | | $ | 49.4 | | | | | | | | | | | | $ | 42.8 | |
| | | | | | | | |
Total assets | | $ | 3,645.8 | | $ | 3,661.3 | | $ | 3,601.6 | | | | | | $ | 1,455.5 | | $ | 1,453.1 | | $ | 1,506.0 | | | | |
Less: assets from discontinued operations | | | — | | | — | | | — | | | | | | | — | | | — | | | — | | | | |
Less: accounts payable | | | 123.8 | | | 127.9 | | | 123.1 | | | | | | | 107.3 | | | 88.5 | | | 118.3 | | | | |
Less: other accrued liabilities | | | 270.7 | | | 266.5 | | | 207.0 | | | | | | | 119.3 | | | 124.7 | | | 89.1 | | | | |
Less: liabilities from businesses held for sale | | | — | | | — | | | — | | | | | | | — | | | — | | | — | | | | |
Less: deferred income taxes and other liabilities | | | 203.5 | | | 203.9 | | | 180.0 | | | | | | | 46.2 | | | 46.6 | | | 44.4 | | | | |
Less: goodwill and other intangibles, net | | | 1,945.4 | | | 1,952.2 | | | 1,910.5 | | | | | | | 454.8 | | | 453.7 | | | 453.4 | | | | |
Less: cash and equivalents | | | 445.7 | | | 469.5 | | | 503.0 | | | | | | | 136.9 | | | 144.9 | | | 197.8 | | | | |
Less: short-term investments available for sale | | | — | | | — | | | — | | | | | | | — | | | — | | | — | | | | |
| | | | | | | | | | | | | | | | | | | | | | | | | | |
Tangible capital | | $ | 656.7 | | $ | 641.3 | | $ | 678.0 | | $ | 658.7 | | | $ | 591.0 | | $ | 594.7 | | $ | 603.0 | | $ | 596.2 | |
Multiplied by weighted average cost of capital | | | | | | | | | | | | 2.3 | % | | | | | | | | | | | | 2.3 | % |
| | | | | | | | | | | | | | | | | | | | | | | | | | |
Capital charge | | | | | | | | | | | $ | 15.2 | | | | | | | | | | | | $ | 13.7 | |
Economic profit | | | | | | | | | | | $ | 34.2 | | | | | | | | | | | | $ | 29.1 | |
Revenue | | | | | | | | | | | $ | 623.2 | | | | | | | | | | | | $ | 423.6 | |
Economic profit margin | | | | | | | | | | | | 5.49 | % | | | | | | | | | | | | 6.87 | % |
(1) | Tangible Capital is a quarterly average calculated as total assets allocated to the segment less (total liabilities allocated to the segment, goodwill and intangibles, cash and equivalents and short term investments available for sale) |
(2) | The sum of the components may not equal the total due to rounding |
CARDINAL HEALTH, INC. AND SUBSIDIARIES
GAAP / NON-GAAP RECONCILIATION
| | | | | | | | | | | | | | |
| | First Quarter 2008 | |
(in millions, except per Common Share amounts) | | GAAP | | | Special Items | | Impairment Charges and Other | | Non-GAAP | |
Operating Earnings | | | | | | | | | | | | | | |
Amount | | $ | 490 | | | $ | 23 | | | — | | $ | 512 | |
Growth Rate | | | 9 | % | | | | | | | | | 8 | % |
| | | | |
Provision for Income Taxes | | $ | 144 | | | $ | 8 | | | — | | $ | 151 | |
| | | | |
Earnings from Continuing Operations | | | | | | | | | | | | | | |
Amount | | $ | 303 | | | $ | 15 | | | — | | $ | 318 | |
Growth Rate | | | 4 | % | | | | | | | | | 3 | % |
| | | | |
Diluted EPS from Continuing Operations | | | | | | | | | | | | | | |
Amount | | $ | 0.82 | | | $ | 0.04 | | | — | | $ | 0.86 | |
Growth Rate | | | 15 | % | | | | | | | | | 15 | % |
| |
| | First Quarter 2007 | |
| | GAAP | | | Special Items | | Impairment Charges and Other | | Non-GAAP | |
Operating Earnings | | | | | | | | | | | | | | |
Amount | | $ | 451 | | | $ | 22 | | $ | 2 | | $ | 475 | |
Growth Rate | | | 23 | % | | | | | | | | | 23 | % |
| | | | |
Provision for Income Taxes | | $ | 122 | | | $ | 6 | | $ | 1 | | $ | 128 | |
| | | | |
Earnings from Continuing Operations | | | | | | | | | | | | | | |
Amount | | $ | 291 | | | $ | 16 | | $ | 1 | | $ | 309 | |
Growth Rate | | | 24 | % | | | | | | | | | 24 | % |
| | | | |
Diluted EPS from Continuing Operations | | | | | | | | | | | | | | |
Amount | | $ | 0.71 | | | $ | 0.04 | | | — | | $ | 0.75 | |
The sum of the components may not equal the total due to rounding
CARDINAL HEALTH, INC. AND SUBSIDIARIES
GAAP / NON-GAAP RECONCILIATION
| | | | | | | | |
| | First Quarter | |
(in millions) | | 2008 | | | 2007 | |
GAAP Return on Equity | | | 16.7 | % | | | 12.8 | % |
| | |
Non-GAAP Return on Equity | | | | | | | | |
Net earnings | | $ | 301.8 | | | $ | 270.7 | |
Special items, net of tax, in continuing operations | | | 14.8 | | | | 16.3 | |
Special items, net of tax, in discontinued operations | | | — | | | | 1.4 | |
| | | | | | | | |
Adjusted net earnings | | $ | 316.6 | | | $ | 288.4 | |
Annualized | | $ | 1,266.4 | | | $ | 1,153.6 | |
| | |
Divided by average shareholders’ equity1 | | $ | 7,222.6 | | | $ | 8,455.9 | |
| | |
Non-GAAP return on equity | | | 17.5 | % | | | 13.6 | % |
| |
| | First Quarter | |
(in millions) | | 2008 | | | 2007 | |
GAAP Return on Invested Capital | | | 6.57 | % | | | 5.14 | % |
| | |
Non-GAAP Return on Invested Capital | | | | | | | | |
Net earnings | | $ | 301.8 | | | $ | 270.7 | |
Special items, net of tax, in continuing operations | | | 14.8 | | | | 16.3 | |
Special items, net of tax, in discontinued operations | | | — | | | | 1.4 | |
Interest expense and other, net of tax | | | 27.5 | | | | 23.6 | |
| | | | | | | | |
Adjusted net earnings | | $ | 344.1 | | | $ | 312.0 | |
| | |
Annualized | | $ | 1,376.4 | | | $ | 1,248.0 | |
| | |
Divided by average total invested capital2 | | $ | 18,365.9 | | | $ | 21,050.9 | |
| | |
Non-GAAP return on invested capital | | | 7.50 | % | | | 5.93 | % |
1 | The average shareholders’ equity shown above is calculated using the average of the prior years’ fourth quarter and the current quarter. |
2 | The average total invested capital shown above is calculated using the average of the prior years’ quarter and the current quarter. Total invested capital is calculated as the sum of the current portion of long-term obligations and other short-term borrowings, long-term obligations, current portion of long-term obligations and other short-term borrowings in discontinued operations, long-term obligations in discontinued operations, total shareholders’ equity and unrecorded goodwill. Unrecorded goodwill is $7.5 billion and $9.7 billion, respectively, for the September 30, 2007 and 2006 calculations. Current portion of long-term obligations and other short-term borrowings in discontinued operations, and long-term obligations in discontinued operations were $59.2 million and $46.6 million at June 30, 2006 and September 30, 2006, respectively. |
CARDINAL HEALTH, INC. AND SUBSIDIARIES
GAAP / NON-GAAP RECONCILIATION
| | | | | | | | |
| | First Quarter | |
(in millions) | | 2008 | | | 2007 | |
GAAP Effective Tax Rate from Continuing Operations | | | 32.2 | % | | | 29.5 | % |
| | |
Non-GAAP Effective Tax Rate from Continuing Operations | | | | | | | | |
Earnings before income taxes and discontinued operations | | $ | 446.9 | | | $ | 413.4 | |
Special items | | | 22.5 | | | | 22.1 | |
| | | | | | | | |
Adjusted earnings before income taxes and discontinued operations | | $ | 469.4 | | | $ | 435.5 | |
| | |
Provision for income taxes | | $ | 143.7 | | | $ | 122.0 | |
Special items tax benefit | | | 7.7 | | | | 5.8 | |
| | | | | | | | |
Adjusted provision for income taxes | | $ | 151.4 | | | $ | 127.8 | |
| | |
Non-GAAP effective tax rate from continuing operations | | | 32.3 | % | | | 29.4 | % |
| |
| | First Quarter | |
| | 2008 | | | 2007 | |
Debt to Total Capital | | | 35 | % | | | 26 | % |
| | |
Net Debt to Capital | | | | | | | | |
Current portion of long-term obligations and other short-term borrowings | | $ | 386.8 | | | $ | 280.1 | |
Long-term obligations, less current portion and other short-term borrowings | | | 3,347.5 | | | | 2,616.0 | |
| | | | | | | | |
Debt | | $ | 3,734.3 | | | $ | 2,896.1 | |
Cash and equivalents | | | (1,289.6 | ) | | | (1,444.1 | ) |
Short-term investments available for sale | | | — | | | | (456.5 | ) |
| | | | | | | | |
Net debt | | $ | 2,444.7 | | | $ | 995.5 | |
Total shareholders’ equity | | $ | 7,068.2 | | | $ | 8,421.1 | |
Capital | | $ | 9,512.9 | | | $ | 9,416.6 | |
Net debt to capital | | | 26 | % | | | 11 | % |
Forward-Looking Non-GAAP Financial Measures
The Company presents non-GAAP operating earnings, non-GAAP earnings from continuing operations, non-GAAP return on equity and non-GAAP effective tax rate from continuing operations (and presentations derived from these financial measures) on a forward-looking basis. The most directly comparable forward-looking GAAP measures are operating earnings, earnings from continuing operations, return on equity and effective tax rate from continuing operations. The Company is unable to provide a quantitative reconciliation of these forward-looking non-GAAP measures to the most comparable forward-looking GAAP measures because the Company cannot reliably forecast special items and impairment charges and other, which are difficult to predict and estimate and are primarily dependent on future events. Please note that the unavailable reconciling items could significantly impact the Company’s future financial results.
CARDINAL HEALTH, INC. AND SUBSIDIARIES
DEFINITIONS
GAAP
Debt: long-term obligations plus short-term borrowings
Debt to Total Capital: debt divided by (debt plus total shareholders’ equity)
Diluted EPS from Continuing Operations: earnings from continuing operations divided by diluted weighted average shares outstanding
Effective Tax Rate from Continuing Operations: provision for income taxes divided by earnings before income taxes and discontinued operations
Operating Cash Flow: net cash provided by / (used in) operating activities from continuing operations
Segment Profit: segment revenue minus (segment cost of products sold and segment selling, general and administrative expenses)
Segment Profit Margin: segment profit divided by revenue
Segment Profit Mix: segment profit divided by total segment profit for all operating segments
Return on Equity:annualized net earnings divided by average shareholders’ equity
Return on Invested Capital: annualized net earnings divided by (average total shareholders’ equity plus debt plus unrecorded goodwill)
Revenue Mix:segment revenue divided by total revenue for all segments
NON-GAAP
Economic Profit:segment net operating earnings, after-tax minus (tangible capital multiplied by weighted average cost of capital);Tangible Capital is the quarterly average calculated as total assets allocated to the segment less (total liabilities allocated to the segment, goodwill and intangibles, cash and equivalents and short term investments available for sale)
Economic Profit Margin:economic profit divided by revenue
Net Debt to Capital: net debt divided by (net debt plus total shareholders’ equity)
Net Debt:debt minus (cash and equivalents and short-term investments available for sale)
Non-GAAP Diluted EPS from Continuing Operations: non-GAAP earnings from continuing operations divided by diluted weighted average shares outstanding
Non-GAAP Diluted EPS from Continuing Operations Growth Rate:(current period non-GAAP diluted EPS from continuing operations minus prior period non-GAAP diluted EPS from continuing operations) divided by prior period non-GAAP diluted EPS from continuing operations
Non-GAAP Earnings from Continuing Operations:earnings from continuing operations excluding special items and impairment charges and other, both net of tax
Non-GAAP Earnings from Continuing Operations Growth Rate: (current period non-GAAP earnings from continuing operations minus prior period non-GAAP earnings from continuing operations) divided by prior period non-GAAP earnings from continuing operations
Non-GAAP Effective Tax Rate from Continuing Operations: (provision for income taxes adjusted for special items) divided by earnings before income taxes and discontinued operations adjusted for special items)
Non-GAAP Operating Earnings: operating earnings excluding special items and impairment charges and other
Non-GAAP Operating Earnings Growth Rate:(current period non-GAAP operating earnings minus prior period non-GAAP operating earnings) divided by prior period non-GAAP operating earnings
Non-GAAP Return on Equity:(annualized current period net earnings plus special items minus special items tax benefit) divided by average shareholders’ equity
Non-GAAP Return on Invested Capital: (annualized net earnings plus special items minus special items tax benefit plus interest expense and other, net of tax) divided by (average total shareholders’ equity plus debt plus unrecorded goodwill)
###